OHSU

IRB #

IRB00005254

Title

A Phase II Study of CTLA Blockade by Ipilimumab plus Androgen Suppression Therapy in Patients with an Incomplete Response to AST Alone for Metastatic Prostate Cancer

Principal Investigator

Julie Graff

Study Purpose

The purpose of this study is to learn how effective the study drug (Ipilimumab, MDX-010, BMS-734016) is against prostate cancer which has stopped responding to treatment with hormone therapy. Also, this study will be looking at the effects of the study drug on the body, and how it effects your immune system.

Medical Condition(s)

Prostate

Eligibility Criteria

* Subjects should have confirmed adenocarcinoma of the prostate that has spread outside of the prostate
* Subjects should not have HIV and/or hepatitis B and/or C.
* Subjects should not have brain metastases.

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

Up to 5 years

Minors Included

No

Contact

Clinical Trials Information Line: Phone 503-494-1080 or trials@ohsu.edu

Sponsor

Bristol-Myers Squibb

Recruitment End

Compensation Provided

No


Go Back